CROI 2017 Program and Information

Program and Agenda

421LB HPTN076: TMC278 LA SAFE, TOLERABLE, AND ACCEPTABLE FOR HIV PRE-EXPOSURE PROPHYLAXIS Linda-Gail Bekker 1 , Shuying S. Li 2 , Betsy Tolley 3 , Mark A. Marzinke 4 , Nyaradzo Mgodi 5 , Jessica E. Justman 6 , Shobha Swaminathan 7 , Adeola Adeyeye 8 , Jennifer H. Farrior 3 , Nirupama Sista 3 1 Univ of Cape Town, Cape Town, South Africa, 2 FRCHC, Seattle, WA, USA, 3 FHI 360, Durham, NC, USA, 4 Johns Hopkins Univ, Baltimore, MD, USA, 5 Univ of Zimbabwe, Harare, Zimbabwe, 6 ICAP at Columbia Univ, New York, NY, USA, 7 Rutgers Univ, Newark, NJ, USA, 8 NIH, Rockville, MD, USA 422LB TRANSCUTANEOUS REFILLABLE NANOFLUIDIC IMPLANT FOR CONSTANT DELIVERY OF HIV PREP Corrine Xuan Chua 1 , Priya Jain 1 , Ming Hu 2 , Peter L. Anderson 3 , Jason T. Kimata 4 , Jagannadha Sastry 5 , Roberto Arduino 5 , Alessandro Grattoni 1 1 Houston Methodist Rsr Inst, Houston, TX, USA, 2 Univ of Houston, Houston, TX, USA, 3 Univ of Colorado Denver, Aurora, CO, USA, 4 Baylor Coll of Med, Houston, TX, USA, 5 Univ of Texas, Houston, TX, USA

Poster P-H2 ANTIRETROVIRAL CLINICAL TRIALS Poster Hall - 4 EF

2:30 PM - 4:00 PM

Poster Sessions • Tuesday

441 WITHDRAWN

-

442 LONG-TERMSAFETY AND EFFICACY OF CAB AND RPV AS 2-DRUG ORALMAINTENANCE THERAPY David A. Margolis 1 , Cynthia Brinson 2 , Graham H. Smith 3 , Joseph J. Eron 4 , Gary J. Richmond 5 , Roger P. LeBlanc 6 , Peter E. Williams 7 , William Spreen 1 , Kenneth Sutton 8 , Britt S. Stancil 9 1 ViiV Hlthcare, Rsr Triangle Park, NC, USA, 2 Central Texas Clinical Rsr, Austin, TX, USA, 3 Maple Leaf Med Clinic, Toronto, Ontario, Canada, 4 Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 5 Gary J Richmond MD PA, Ft Lauderdale, FL, USA, 6 Clinique OPUS, Montréal, Québec, Canada, 7 Janssen Rsr and Development, Beerse, Belgium, 8 ViiV Hlthcare, Raleigh, NC, USA, 9 PAREXEL Intl, Durham, NC, USA 443 EFFICACY & SAFETY OF SWITCHING TO EVG/COBI/FTC/TAF IN VIROLOGICALLY SUPPRESSEDWOMEN Sally Hodder 1 , Kathleen Squires 2 , Cissy Kityo 3 , Debbie Hagins 4 , Anchalee Avihingsanon 5 , Yulia Plotnikova 6 , Shuping Jiang 7 , Rima Kulkarni 7 , Andrew Cheng 7 , Huyen Cao 7 1 West Virginia Clinical and Translational Sci Inst, Morgantown, WV, USA, 2 Thomas Jefferson Univ, Philadelphia, PA, USA, 3 Joint Clinical Rsr Cntr, Kampala, Uganda, 4 Chatham CARE Cntr, Savannah, GA, USA, 5 HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 6 Irkutsk Regional Cntr for Prevention and Control of AIDS and Infectious Diseases, Irkutsk, Russian Federation, 7 Gilead Scis, Inc, Foster City, CA, USA 444 THE FDA SNAPSHOT ALGORITHMMAY OVERESTIMATE THE EFFICACY OF INITIAL ART Stephen J. Kerr 1 , Andrew Carr 2 1 The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2 St. Vincent’s Hosp, Sydney, Australia

CROI 2017 86